Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Dova Pharmaceuticals Inc (DOVA)

Dova Pharmaceuticals Inc (DOVA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 418,205
  • Shares Outstanding, K 28,802
  • Annual Sales, $ 10,360 K
  • Annual Income, $ -72,280 K
  • 60-Month Beta 2.57
  • Price/Sales 41.22
  • Price/Cash Flow N/A
  • Price/Book 8.24

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -0.62
  • Number of Estimates 4
  • High Estimate -0.59
  • Low Estimate -0.66
  • Prior Year -0.69
  • Growth Rate Est. (year over year) +10.14%

Price Performance

See More
Period Period Low Period High Performance
1-Month
14.49 +0.21%
on 08/16/19
16.84 -13.78%
on 08/08/19
-1.55 (-9.65%)
since 07/16/19
3-Month
7.97 +82.15%
on 06/12/19
18.14 -19.96%
on 07/05/19
+3.89 (+36.59%)
since 05/16/19
52-Week
5.62 +158.36%
on 12/20/18
26.49 -45.19%
on 08/30/18
-8.48 (-36.87%)
since 08/16/18

Most Recent Stories

More News
Dova Pharmaceuticals to Present at 2019 Wedbush PacGrow Healthcare Conference

Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) today announced that Jason Hoitt, Chief Commercial Officer, will present a company overview at the 2019 Wedbush PacGrow Healthcare Conference on Tuesday, August...

DOVA : 14.52 (-2.02%)
Dova Pharmaceuticals (DOVA) Reports Q2 Loss, Lags Revenue Estimates

Dova Pharmaceuticals (DOVA) delivered earnings and revenue surprises of -5.26% and -37.55%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

DOVA : 14.52 (-2.02%)
Dova Pharmaceuticals: 2Q Earnings Snapshot

DURHAM, N.C. (AP) _ Dova Pharmaceuticals Inc. (DOVA) on Tuesday reported a loss of $17.1 million in its second quarter.

DOVA : 14.52 (-2.02%)
Dova Pharmaceuticals Reports Second Quarter 2019 Operating and Financial Results

-- DOPTELET approved by European Commission (EC) for treatment of severe thrombocytopenia in patients with chronic liver disease (CLD)

DOVA : 14.52 (-2.02%)
Dova Pharmaceuticals to Announce Second Quarter 2019 Financial Results on August 6, 2019

Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) will host a conference call on Tuesday, August 6, 2019 at 9:00 a.m. ET to discuss second quarter 2019 financial results and recent operational highlights. A question-and-answer...

DOVA : 14.52 (-2.02%)
Dova Pharmaceuticals Announces DOPTELET(R) (avatrombopag) Now Commercially Available in the United States for Treatment of Chronic Immune Thrombocytopenia (ITP)

Dova Pharmaceuticals, Inc. (NASDAQ: DOVA), a pharmaceutical company focused on acquiring, developing and commercializing drug candidates for diseases where there is a high unmet need, today announced the...

DOVA : 14.52 (-2.02%)
Dova Pharmaceuticals (DOVA) in Focus: Stock Moves 9.1% Higher

Dova Pharmaceuticals (DOVA) shares rose more than 9% in the last trading session, amid huge volumes.

CPIX : 5.63 (+2.16%)
DOVA : 14.52 (-2.02%)
Bausch Gains 38.9% YTD on Product Launches & Debt Reduction

Bausch (BHC) is currently focusing on widening its ophthalmology and dermatology portfolio.

DOVA : 14.52 (-2.02%)
ADMS : 6.42 (+2.23%)
BHC : 21.30 (+2.01%)
ACST : 1.91 (+9.14%)
Dova Receives Approval for Doptelet in Europe, Stock Up

Dova Pharmaceuticals (DOVA) announces approval of its thrombocytopenia drug, Doptelet, in Europe for patients with chronic liver disease.

DOVA : 14.52 (-2.02%)
NVS : 89.47 (+1.00%)
RIGL : 1.94 (+1.04%)
BHC : 21.30 (+2.01%)
Dova Pharmaceuticals Announces FDA Approval of Supplemental New Drug Application for DOPTELET(R) (avatrombopag) for Treatment of Chronic Immune Thrombocytopenia (ITP)

Company Strengthens Thrombocytopenia Portfolio with ITP Approval and Expanded Partnership with Salix for Chronic Liver Disease (CLD) Indication

DOVA : 14.52 (-2.02%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade DOVA with:

Business Summary

Dova Pharmaceuticals, Inc. is a pharmaceutical company. It focuses on acquiring, developing and commercializing drug candidates for thrombocytopenia diseases. The company's drug candidate includes avatrombopag, an orally administered thrombopoietin receptor agonist which are in clinical stage. Dova Pharmaceuticals,...

See More

Key Turning Points

2nd Resistance Point 15.29
1st Resistance Point 14.90
Last Price 14.52
1st Support Level 14.31
2nd Support Level 14.11

See More

52-Week High 26.49
Fibonacci 61.8% 18.52
Fibonacci 50% 16.06
Last Price 14.52
Fibonacci 38.2% 13.59
52-Week Low 5.62

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar